Long-term low molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study

Lancet

Volumn 354, Issue 9180, 1999, Pages 701-707

  Ragmin, F ^a   Wallentin, L ^a   Swahn, E ^a   Kontny, F ^a   Husted, S ^a   Lagerqvist, B ^a   Stahle, E ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCANDINAVIA; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

EID: 0033612915     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)07350-X     Document Type: Article

References (22)

1. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
2. Klein W., Buchwald A., Hillis S.E.et al. Comparison of low molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation. 96:1997;61-68.
3. Cohen M., Demers C., Gurfinkel E.P.et al. A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 337:1997;447-452.
4. Van Belle E., Lablanche J.M., Bauters C., Renaud N., McFadden E.P., Bertrand M.E. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation. 97:1998;2-33.
5. Merlini P., Bauer K., Oltrona L.et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
6. Ernofsson M., Strekerud F., Toss H., Abildgaard U., Wallentin L. Low molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost. 79:1998;491-494.
7. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
8. A comparison of aspirin plus tirofiban versus aspirin plus heparin for unstable angina. N Engl J Med. 228:1998;1498-1505.
9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
10. Inhibition of platelet glycoprotien IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
11. Theroux P., Waters D., Lam J.et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
12. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, for unstable coronary artery disease in 1209 patients. Eur Heart J. 18:1997;1416-1425.
13. Lindahl B., Venge P., Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol. 29:1997;43-48.
14. Nyman I., Wallentin L., Areskog M., Areskog N.H., Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease: The RISC Study Group. Int J Cardiol. 39:1993;131-142.
15. Campbell R.W.F., Wallentin L., Verheugt F.W.A.et al. Managment strategies for a better outcome in unstable coronary artery disease. Clin Cardiol. 21:1998;314-322.
16. Thèroux P., Fuster V. Acute Coronary Syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 97:1998;1195-1206.
17. Toss H., Wallentin L., Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 137:1999;72-78.
18. Anand S.S., Yusuf S., Pogue J., Weitz J.I., Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspect non-Q-wave myocardial infarction. Circulation. 98:1998;1064-1070.
19. Antman E., McCabe C.H., Premmereur J.et al. Enoxaparin for the acute and chronic management of unstable angina/non-Q-wave myocardial infarction: results from the TIMI 11B study. Circulation. 98:1998;504.
20. Leizorovicz A. Preliminary results from the FRAX.I.S. study: oral presentation, hotline session. 1998;European Society of Cardiology Scientific Sessions, Vienna.
21. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 2:1980;989-993.
22. Grip L., Blomback M., Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J. 12:1991;1225-1233.